(Q38196939)

30 August 2017

1 reference

title

Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies (English)

1 reference

metastatic renal cell carcinoma

30 August 2017

1 reference

1 reference

Elena Verzoni

6

0 references

Giuseppe Procopio

object named as

Giuseppe Procopio

3

0 references

author name string

Sergio Bracarda

1

1 reference

30 August 2017

Daniel Castellano

2

1 reference

30 August 2017

Juan M Sepúlveda

4

1 reference

30 August 2017

Michele Sisani

5

1 reference

30 August 2017

Manuela Schmidinger

7

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 April 2014

1 reference

Expert Opinion on Drug Safety

30 August 2017

published in

1 reference

30 August 2017

volume

13

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

497-510

1 reference

Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Axitinib for the management of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Experience with sorafenib and adverse event management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Clinically relevant fatigue in recurrence-free prostate cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

SU11248 and AG013736: current data and future trials in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Sequencing systemic therapies in advanced RCC: is there a best strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Marked response of burning mouth syndrome to pregabalin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888413

10.1517/14740338.2014.888413

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference